Chemistry:ASR-3001

From HandWiki

ASR-3001, also known as 5-methoxy-N-isopropyl-N-allyltryptamine (5-MeO-iPALT), is a serotonin receptor agonist and serotonergic psychedelic of the tryptamine and 5-methoxytryptamine families which is under development for the treatment of psychiatric disorders.[1][2][3][4][5] It is a close analogue of related psychedelic tryptamines like 5-MeO-DALT, 5-MeO-DiPT, and 5-MeO-MiPT.[5] The drug is taken orally.[2]

Use and effects

ASR-3001 is said to be orally active, fast- and short-acting, and to induce "an internal psychedelic cognitive state [or head space] with little or no sensory [or visual] involvement".[2][3][4][6] More specifically, it is said to have an absence of open-eye and closed-eye visuals.[6] These properties are expected to allow ASR-3001 to serve as a potential "entry point" for people reluctant to undergo a fully immersive psychedelic experience that includes visuals.[2][6] ASR-3001 is said to be internally psychedelic as opposed to entactogenic.[6] Its dose range is 8 to 14 mg (or perhaps up to 10 mg), its onset is within 15 minutes or as fast as 6 to 8 minutes, and its duration is short at about 1.5 to 2.5 hours (90–150 minutes).[2][3][4][6] Along with 4-HO-DiPT, it appears to be one of the shortest-acting oral psychedelics known.[6][2][7][8]

Interactions

Pharmacology

Pharmacodynamics

ASR-3001 acts as a non-selective agonist of the serotonin receptors.[5] This includes of the serotonin 5-HT2A, 5-HT2B, 5-HT1A, 5-HT1B, and 5-HT6 receptors, whereas other serotonin receptors, such as the serotonin 5-HT2C receptor, were not described.[5] Its EC50 values were 9.85 nM at the serotonin 5-HT2A receptor, 46.8 nM at the serotonin 5-HT1B receptor, 87.4 nM at the serotonin 5-HT2B receptor, 420 nM at the serotonin 5-HT6 receptor, and 642 nM at the serotonin 5-HT1A receptor.[5] The drug was also a very weak serotonin reuptake inhibitor (IC50 = 6,840 nM), but did not inhibit norepinephrine or dopamine reuptake.[5] It showed little or no activity at various other sites as well.[5]

Chemistry

Analogues

Analogues of ASR-3001 (5-MeO-iPALT) include isopropylallyltryptamine (iPALT; ASR-3003), 5-MeO-DMT, 5-MeO-DiPT, 5-MeO-DALT, 5-MeO-MiPT, 5-MeO-EiPT, 5-MeO-PiPT, 5-MeO-MALT, and 5-MeO-EPT, among others.[7] Other analogues include ASR-3002 (2-Me-iPALT), and ASR-3004 (PALT), among others.[5]

History

ASR-3001 was first described by 2023 and was patented the same year.[2][5]

Society and culture

Canada

ASR-3001 is not an explicitly nor implicitly controlled substance in Canada as of 2025.[9]

United States

ASR-3001 is not an explicitly controlled substance in the United States.[10] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

Research

ASR-3001 is under development by the Nicholas V. Cozzi and Paul F. Daley and colleagues at the Alexander Shulgin Research Institute (ASRI).[1][2][6] As of early 2025, it is in the preclinical research stage of development.[1][11] The drug is the ASRI's most advanced developmental candidate.[6]

See also

References

  1. ↑ 1.0 1.1 1.2 "Delving into the Latest Updates on Tryptamine(ASRI) with Synapse". 16 April 2025. https://synapse.patsnap.com/drug/f892ced734124e219284101df5c71d42. 
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 "Pioneering Psychedelics Scientist Alexander "Sasha" Shulgin's Legacy Lives On Via New Compounds And Research". 10 July 2023. https://www.benzinga.com/markets/cannabis/23/07/33171977/pioneering-psychedelics-scientist-alexander-sasha-shulgins-legacy-lives-on-via-new-compounds-and. 
  3. ↑ 3.0 3.1 3.2 "The Heirs to a Vault of Novel Psychedelics Take a Trip Into the Unknown". 2 November 2023. https://doubleblindmag.com/sasha-shulgin-legacy/. 
  4. ↑ 4.0 4.1 4.2 "What Happens When You Inherit 500 Psychedelic Compounds?". 30 March 2025. https://doubleblindmag.com/what-happens-when-you-inherit-500-psychedelic-compounds/. 
  5. ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 5.8 ; Nicholas Cozzi & Wyeth Baillie Callaway"Asymmetric allyl tryptamines" WO patent 2023034645A2, published 9 March 2023, assigned to Alexander Shulgin Research Institute
  6. ↑ 6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 Cite error: Invalid <ref> tag; no text was provided for refs named MooreDaley2024
  7. ↑ 7.0 7.1 Shulgin, Alexander; Shulgin, Ann (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252. http://www.erowid.org/library/books_online/tihkal/tihkal.shtml. 
  8. ↑ Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628. http://www.erowid.org/library/books_online/pihkal/pihkal.shtml. 
  9. ↑ "Controlled Drugs and Substances Act". 5 December 2025. https://laws-lois.justice.gc.ca/eng/acts/c-38.8/FullText.html. 
  10. ↑ Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026, https://www.deadiversion.usdoj.gov/schedules/orangebook/orangebook.pdf 
  11. ↑ Michael Haichin (2024). "Psychedelics Drug Development Tracker". https://psychedelicalpha.com/data/psychedelic-drug-development-tracker. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:ASR-3001&oldid=4245670"